Corticosteroids for pneumonia
122 results
1 - 100
Corticosteroids for pneumonia
Inhaled corticosteroids increase pneumonia risk in stable COPD
Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV-infection - Corticosteroids improve outcomes in patients with severe community-acquired pneumonia
- Risk of serious pneumonia in COPD patients using inhaled corticosteroids
- Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection
- Systemic corticosteroids reduce need for ICU or mechanical ventilation in patients with community-acquired pneumonia
- Steroids = placebo in community acquired pneumonia
- Inhaled steroids for COPD associated with increased risk of pneumonia
- Steroids beneficial as adjunctive treatment for community-acquired pneumonia
- Inhaled budesonide for COPD not associated with pneumonia
- Inhaled corticosteroids versus placebo for stable chronic obstructive pulmonary disease
- The addition of steroids improves outcomes in children and adults with CAP
- Inhaled corticosteroids versus long‐acting beta2‐agonists for chronic obstructive pulmonary disease
- Updated guidelines from the Society of Critical Care Medicine strongly recommend steroids for hospitalized adults with severe community-acquired pneumonia
- Single course of antenatal steroids associated with small increased incidence of serious infection in infants
- Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
- A single corticosteroid burst in children is associated with harms
- Corticosteroids for acute bacterial meningitis
- Inhaled corticosteroids in COPD
- Dexamethasone for acute bacterial meningitis in children
- A bundle of evidence-based strategies that includes steroids for the treatment of CAP does not improve outcomes
- Dexamethasone reduces LOS in patients with community-acquired pneumonia
- Combined corticosteroid and long-acting beta-agonist in one inhaler for chronic obstructive pulmonary disease
- Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease
- Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus long‐acting beta2‐agonists for chronic obstructive pulmonary disease
- Small study shows steroids may benefit patients with severe CAP and high CRP levels
- One year of inhaled corticosteroid use is not associated with frequent serious harms in adults with asthma
- Corticosteroids as adjunctive therapy in the treatment of influenza
- Corticosteroids for idiopathic pulmonary fibrosis
- Inhaled corticosteroids with combination inhaled long‐acting beta2‐agonists and long‐acting muscarinic antagonists for chronic obstructive pulmonary disease
- Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus placebo for chronic obstructive pulmonary disease
- Convalescent plasma does not improve outcomes in patients hospitalized with severe COVID-19 pneumonia (PlasmAr)
- Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease
- Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease
- HIV infection
- Intravenous hydrocortisone reduces all-cause mortality in severe community-acquired pneumonia (CAPE COD)
- Prophylaxis for Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients
- The American Thoracic Society guideline for managing patients with chronic obstructive pulmonary disease
- Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic antagonists for people with chronic obstructive pulmonary disease
- Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease: Cochrane systematic review
- COVID-19 research briefs: Wuhan patient outcomes, and new Infectious Disease Society of America treatment guidelines
- Dual combination therapy versus long‐acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta‐analysis
- Updated clinical guidelines for the diagnosis and treatment of CAP
- Tiotropium, inhaled steroids and long-acting beta2-agonists alone or in combinations for chronic obstructive pulmonary disease
- Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery